Skip to Main content Skip to Navigation
Journal articles

The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.

Abstract : Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its stimulation by endogenous ligands, EGF or transforming growth factor-alpha (TGF-alpha) results in activation of intracellular tyrosine kinase, therefore, cell cycle progression. High levels of EGFR expression are correlated with poor prognosis and resistance to radiation therapy in a variety of cancers, mostly in squamous-cell carcinoma of the head and neck (SCCHN). Blocking the EGFR by a monoclonal antibody results in inhibition of the stimulation of the receptor, therefore, in inhibition of cell proliferation, enhanced apoptosis, and reduced angiogenesis, invasiveness and metastases. The EGFR is a prime target for new anticancer therapy in SCCHN, and other agents in development include small molecular tyrosine kinase inhibitors and antisense therapies.
Complete list of metadatas

Cited literature [20 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00090010
Contributor : Delphine Autard <>
Submitted on : Friday, August 25, 2006 - 4:15:30 PM
Last modification on : Sunday, November 1, 2020 - 12:10:52 PM
Long-term archiving on: : Tuesday, September 18, 2012 - 4:50:40 PM

Identifiers

Collections

Citation

Michel Zimmermann, Abderrahim Zouhair, David Azria, Mahmut Ozsahin. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.. Radiat Oncol, 2006, 1, pp.11. ⟨10.1186/1748-717X-1-11⟩. ⟨inserm-00090010⟩

Share

Metrics

Record views

431

Files downloads

451